BioWorld

March 6, 2009

View Archived Issues

Proteon Snares $38M Round, and $550M Novartis Option

Proteon Therapeutics Inc. is banking on its lead product to clear a crucial Phase II study, the results of which could seal a $550 million deal with Novartis AG. (BioWorld Today) Read More

Optimer's Anti-Infective Pipeline Moving Ahead Via $33M Offering

Read More

Ortho Group Says Biologics Are no Longer 'Back in the Corner'

Read More

Obama Ties Health Reform To Prosperity of the U.S.

Read More

Isolagen Shares Jump 30% on Good Acne Trial Data

Read More

Other News To Note

Read More

Clinic Roundup

Read More